Circulating thrombin time anticoagulant in a procainamide-induced syndrome.
Circulating anticoagulants are unusual in drug-induced syndromes. We evaluated the prolonged thrombin time of plasma from a patient with a procainamide-induced syndrome. This defect was shown to be due to a circulating anticoagulant that was not of fibrin or fibrinogen origin and that prolonged thrombin and reptilase clotting times of plasma. Subclinical doses of heparin sodium induced hemorrhagic manifestations in this patient. Following cessation of heparin therapy, the circulating anticoagulant persisted but the bleeding tendency abated. All clinical and laboratory manifestations of this syndrome abated gradually following cessation of procainamide therapy.
D000368:Aged; D012103:Batroxobin / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects; D001778:Blood Coagulation Disorders / Q000139:chemically induced*; D001780:Blood Coagulation Tests; D005337:Fibrin / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008297:Male; D011342:Procainamide / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D013577:Syndrome; D013917:Thrombin
D005337:Fibrin; D005340:Fibrinogen; D012103:Batroxobin; D013917:Thrombin; D011342:Procainamide